Using tears to assess Alzheimer’s disease
MicroRNAs (miRNAs), small noncoding regulators controlling approximately 60 per cent of human genes, have strong early diagnostic potential due to their ability to modulate complex gene networks and stability in extracellular fluids. However, blood-based miRNA findings remain inconsistent, highlighting the need for alternative, scalable biofluids. This study aims to demonstrate the translational potential of tear-fluid miRNAs as non-invasive, clinically relevant early biomarkers for diagnosing sporadic Alzheimer’s disease.